Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells

Chemico-Biological Interactions

Volumn 188, Issue 3, 2010, Pages 535-545

  Liu, Huei Fang ^a   Hu, Huai Chin ^b   Chao, Jui I ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Oxaliplatin; P38 MAP kinase; Proteasome; Survivin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PROTEASOME; PROTEIN P53; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DOWN-REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MICROTUBULE-ASSOCIATED PROTEINS; ORGANOPLATINUM COMPOUNDS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRIDINES; RNA, MESSENGER;

EID: 78149464260     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.08.001     Document Type: Article

References (51)

1. Sandor V. Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer. Lancet 1997, 350:1325-1326.
2. Hochster H., Chachoua A., Speyer J., Escalon J., Zeleniuch-Jacquotte A., Muggia F. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. J. Clin. Oncol. 2003, 21:2703-2707.
3. Ramanathan R.K., Clark J.W., Kemeny N.E., Lenz H.J., Gococo K.O., Haller D.G., Mitchell E.P., Kardinal C.G. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J. Clin. Oncol. 2003, 21:2904-2911.
4. Raymond E., Faivre S., Chaney S., Woynarowski J., Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 2002, 1:227-235.
5. Chaney S.G., Campbell S.L., Bassett E., Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 2005, 53:3-11.
6. Gourdier I., Del Rio M., Crabbe L., Candeil L., Copois V., Ychou M., Auffray C., Martineau P., Mechti N., Pommier Y., Pau B. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett. 2002, 529:232-236.
7. Arango D., Wilson A.J., Shi Q., Corner G.A., Aranes M.J., Nicholas C., Lesser M., Mariadason J.M., Augenlicht L.H. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 2004, 91:1931-1946.
8. Chiu S.J., Hsu T.S., Chao J.I. Opposing securin and p53 protein expression in the oxaliplatin-induced cytotoxicity of human colorectal cancer cells. Toxicol. Lett. 2006, 167:122-130.
9. Chiu S.J., Chao J.I., Lee Y.J., Hsu T.S. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol. Lett. 2008, 179:63-70.
10. Ngan C.Y., Yamamoto H., Takagi A., Fujie Y., Takemasa I., Ikeda M., Takahashi-Yanaga F., Sasaguri T., Sekimoto M., Matsuura N., Monden M. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci. 2008, 99:129-139.
11. Zhu A.X., Willett C.G. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin. Radiat. Oncol. 2003, 13:454-468.
12. Kjellstrom J., Kjellen E., Johnsson A. In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line. Acta Oncol. 2005, 44:687-693.
13. Lin J., Hsiao P.W., Chiu T.H., Chao J.I. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem. Pharmacol. 2005, 70:658-667.
14. Fujie Y., Yamamoto H., Ngan C.Y., Takagi A., Hayashi T., Suzuki R., Ezumi K., Takemasa I., Ikeda M., Sekimoto M., Matsuura N., Monden M., Oxaliplatin a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn. J. Clin. Oncol. 2005, 35:453-463.
15. Pectasides D., Pectasides M., Farmakis D., Gaglia A., Koumarianou A., Nikolaou M., Koumpou M., Kountourakis P., Papaxoinis G., Mitrou P., Economopoulos T., Raptis S.A. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. Gynecol. Oncol. 2004, 95:165-172.
16. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3:917-921.
17. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396:580-584.
18. Chao J.I., Kuo P.C., Hsu T.S. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J. Biol. Chem. 2004, 279:20267-20276.
19. Kuo P.C., Liu H.F., Chao J.I. Survivin and p53 modulate quercetin-induced cell growth inhibition and apoptosis in human lung carcinoma cells. J. Biol. Chem. 2004, 279:55875-55885.
20. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999, 13:239-252.
21. Wall N.R., O'Connor D.S., Plescia J., Pommier Y., Altieri D.C. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003, 63:230-235.
22. Lu B., Mu Y., Cao C., Zeng F., Schneider S., Tan J., Price J., Chen J., Freeman M., Hallahan D.E. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004, 64:2840-2845.
23. Chao J.I., Su W.C., Liu H.F. Baicalein induces cancer cell death and proliferation retardation by the inhibition of CDC2 kinase and survivin associated with opposite role of p38 mitogen-activated protein kinase and AKT. Mol. Cancer Ther. 2007, 6:3039-3048.
24. Takekawa M., Adachi M., Nakahata A., Nakayama I., Itoh F., Tsukuda H., Taya Y., Imai K. p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. Embo J. 2000, 19:6517-6526.
25. Schwenger P., Bellosta P., Vietor I., Basilico C., Skolnik E.Y., Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:2869-2873.
26. Li W., Bertino J.R. Fas-mediated signaling enhances sensitivity of human soft tissue sarcoma cells to anticancer drugs by activation of p38 kinase. Mol. Cancer Ther. 2002, 1:1343-1348.
27. Bode A.M., Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4:793-805.
28. Fuster J.J., Sanz-Gonzalez S.M., Moll U.M., Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol. Med. 2007, 13:192-199.
29. Bates S., Vousden K.H. p53 in signaling checkpoint arrest or apoptosis. Curr. Opin. Genet. Dev. 1996, 6:12-18.
30. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
31. Hofseth L.J., Hussain S.P., Harris C.C. p53: 25 years after its discovery. Trends Pharmacol. Sci. 2004, 25:177-181.
32. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80:293-299.
33. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7:683-694.
34. Liu H.F., Hsiao P.W., Chao J.I. Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chem. Biol. Interact 2008, 176:48-57.
35. Kim S.J., Ju J.W., Oh C.D., Yoon Y.M., Song W.K., Kim J.H., Yoo Y.J., Bang O.S., Kang S.S., Chun J.S. ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. J. Biol. Chem. 2002, 277:1332-1339.
36. Ikeguchi M., Ueta T., Yamane Y., Hirooka Y., Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin. Cancer Res. 2002, 8:3131-3136.
37. Hsiao P.W., Chang C.C., Liu H.F., Tsai C.M., Chiu T.H., Chao J.I. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol. Appl. Pharmacol. 2007, 222:97-104.
38. Chao J.I., Yang J.L. Opposite roles of ERK and p38 mitogen-activated protein kinases in cadmium-induced genotoxicity and mitotic arrest. Chem. Res. Toxicol. 2001, 14:1193-1202.
39. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
40. Aramaki Y., Matsuno R., Tsuchiya S. Involvement of p38 MAP Kinase in the inhibitory effects of phosphatidylserine liposomes on nitric oxide production from macrophages stimulated with LPS. Biochem. Biophys. Res. Commun. 2001, 280:982-987.
41. Ghatan S., Larner S., Kinoshita Y., Hetman M., Patel L., Xia Z., Youle R.J., Morrison R.S. p38 MAP kinase mediates bax translocation in nitric oxide-induced apoptosis in neurons. J. Cell Biol. 2000, 150:335-347.
42. Ding H., Han C., Zhu J., Chen C.S., D'Ambrosio S.M. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int. J. Cancer 2005, 113:803-810.
43. Dandekar D.S., Lopez M., Carey R.I., Lokeshwar B.L. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int. J. Cancer 2005, 115:484-492.
44. Dumaz N., Meek D.W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. Embo J. 1999, 18:7002-7010.
45. Canman C.E., Lim D.S. The role of ATM in DNA damage responses and cancer. Oncogene 1998, 17:3301-3308.
46. Meek D.W. Mechanisms of switching on p53: a role for covalent modification?. Oncogene 1999, 18:7666-7675.
47. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102:849-862.
48. Hoffman W.H., Biade S., Zilfou J.T., Chen J., Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002, 277:3247-3257.
49. Siegelin M.D., Reuss D.E., Habel A., Herold-Mende C., von A., Deimling the flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. Mol. Cancer Ther. 2008, 7:3566-3574.
50. Ho A.K., McNeil L., Terriff D., Price D.M., Chik C.L. Role of protein turnover in the activation of p38 mitogen-activated protein kinase in rat pinealocytes. Biochem. Pharmacol. 2005, 70:1840-1850.
51. Navas T.A., Nguyen A.N., Hideshima T., Reddy M., Ma J.Y., Haghnazari E., Henson M., Stebbins E.G., Kerr I., O'Young G., Kapoun A.M., Chakravarty S., Mavunkel B., Perumattam J., Luedtke G., Dugar S., Medicherla S., Protter A.A., Schreiner G.F., Anderson K.C., Higgins L.S. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 2006, 20:1017-1027.